|
| 羧酸酯酶-2和拓扑异构酶1的表达对伊立替康联合铂类治疗小细胞肺癌的预测意义初探 |
| Prognostic Implication of Expression of Carboxylesterase 2 and Topoisomerase 1 in Small Cell Lung Cancer with Irinotecan Combined with Platinum Treatment |
| |
| DOI： |
| 中文关键词: 小细胞肺癌 羧酸酯酶-2 拓扑异构酶1 伊立替康 |
| 英文关键词:Small cell lung cancer Carboxylesterase 2 Topoisomerase 1 Irinotecan |
| 基金项目:中央高校基本科研业务费项目（HUST：2013ZHYX013） |
|
| 摘要点击次数: 1076 |
| 全文下载次数: 1105 |
| 中文摘要: |
| 摘 要 目的:探讨小细胞肺癌组织中羧酸酯酶-2（CES-2）和拓扑异构酶1（topo1）的表达对伊立替康（CPT-11）联合铂类化疗预后的临床意义。方法：分别应用免疫组化方法和酶联免疫吸附方法检测接受CPT-11联合铂类治疗的48例小细胞肺癌患者组织CES-2表达和topo1活性，并与患者化疗的临床预后如无疾病进展期（PFS）和总生存期（OS）进行比较。结果：48例小细胞肺癌标本中，CES-2阳性比为72.9%，topo1活性为（22 459±5 422）U·mg-1 protein，CES-2表达及topo1活性在不同分期小细胞肺癌患者中差异均无统计学意义（P>0.05）。不同分期小细胞肺癌患者CES-2是否表达与其中位PFS及OS差异亦均无统计学意义（P>0.05）。31例局限期小细胞肺癌患者中，CES-2表达阳性的中位PFS及OS分别是12.3，18个月；CES-2表达阴性的中位PFS及OS分别是10.9，17.6个月。17例广泛期小细胞肺癌患者中，CES-2表达阳性的中位PFS及OS分别是10.5，14.1个月；CES-2表达阴性的中位PFS及OS分别是10.2，13.8个月。结论：CES-2表达和topo1活性尚不足以预测CPT-11联合铂类治疗小细胞肺癌的预后，有待扩大样本量进一步从疗效、毒性及预后方面同时考察。 |
| 英文摘要: |
| ABSTRACT Objective:To explore the prognosis of expression of carboxylesterase 2 (CES-2) and topoisomerase 1 (Topo1) in small cell lung cancer (SCLC) on irinotecan combined with platinum chemotherapy.Methods:Using the immunohistochemical and ELISA method detected the expression of human CES-2 and Topo1 respectively in 48 patients treated with irinotecan (CPT-11) and platinum regimen, and comparison with progression free survival (PFS) and overall survival (OS). Results:Among 48 cases, the positive rate of CES-2 expression was 72.9%, the totaltopo1 activity (22 459 ± 5 422)U·mg-1 protein, but significant difference was not observed in CES-2 and Topo1 expression between different stages (P>0.05). Moreover, PFS and OS in CES-2 positive or CES-2 negative patients were also not significantly different in LD SCLC and ED SCLC stages (P>0.05). 31 cases with LD SCLC, the PFS and OS of CES-2 positive expression were 12.3 and 18 months respectively, and PFS and OS of CES-2 negative expression were 10.9 and 17.6 months respectively. 17 cases with ED SCLC，the PFS and OS of CES-2 positive expression were 10.5 and 14.1 months respectively, and PFS and OS of CES-2 negative expression were 10.2 and 13.8 months respectively. Conclusion:Expression of CES-2 and Topo1 failed to predict the efficacy of CPT-11 in SCLC. It should be further study on the effect, toxicity and prognosis. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
